Advertisement
UK markets closed
  • NIKKEI 225

    38,202.37
    -632.73 (-1.63%)
     
  • HANG SENG

    18,313.86
    -165.51 (-0.90%)
     
  • CRUDE OIL

    79.21
    +0.83 (+1.06%)
     
  • GOLD FUTURES

    2,316.80
    -7.40 (-0.32%)
     
  • DOW

    39,056.39
    +172.13 (+0.44%)
     
  • Bitcoin GBP

    49,312.91
    -1,136.89 (-2.25%)
     
  • CMC Crypto 200

    1,307.04
    +12.37 (+0.96%)
     
  • NASDAQ Composite

    16,302.76
    -29.80 (-0.18%)
     
  • UK FTSE All Share

    4,544.24
    +21.25 (+0.47%)
     

Upadacitinib Could Drive AbbVie’s Long-Term Growth

Upadacitinib Could Drive AbbVie’s Long-Term Growth

In April 2018, AbbVie (ABBV) positive results for its Phase 3 SELECT-COMPARE trial, which evaluated the safety and efficacy of upadacitinib for adults with moderate-to-severe rheumatoid arthritis. The trial met its primary endpoint of improved ACR201 scores and clinical remission.